Tango Therapeutics Q1 2024 GAAP EPS $(0.35) Misses $(0.31) Estimate, Sales $6.471M Miss $6.669M Estimate
Author: Benzinga Newsdesk | May 08, 2024 07:35am
Tango Therapeutics (NASDAQ:
TNGX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.31) by 12.9 percent. This is a 9.37 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $6.471 million which missed the analyst consensus estimate of $6.669 million by 2.98 percent. This is a 12.23 percent increase over sales of $5.766 million the same period last year.
Posted In: TNGX